The most significant study demonstrating a lack of a protective role for IFN-γ in pulmonary fibrosis is the result of the INSPIRE clinical trial, which concluded that IFN-γ treatment in patients with idiopathic pulmonary fibrosis had no therapeutic effect [35]. Here, IFNG is linked to idiopathic pulmonary fibrosis.